Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension
Authors:
- Roy HarperRHRoy Harper
- Cieran N. EnnisCECieran N. Ennis
- Elizabeth CrothersECElizabeth Crothers
- Brian SheridanBSBrian Sheridan
- G Dennis JohnstonGJG Dennis Johnston
- A Brew AtkinsonAAA Brew Atkinson
- Patrick M. BellPBPatrick M. Bell
- 1 January 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 16 (1) , 103-109
Abstract
To determine whether combination of an angiotensin converting enzyme inhibitor with a high dose of thiazide diuretic avoids adverse metabolic consequences of thiazide diuretics. Double-blind randomized crossover study of two 12-week treatment periods with captopril (up to 100 mg/day) either alone or in combination with 5 mg bendrofluazide given after a 6-week placebo run-in period. Treatment periods were separated by a 6-week placebo washout period. Outpatient clinics in greater Belfast. Fifteen white non-diabetic essential hypertensives (seven male) aged < 65 years recruited from general practices in greater Belfast. Systolic and diastolic blood pressures and peripheral and hepatic insulin action. Two patients failed to complete the study. Blood pressure was lowered (139/89 ± 18/7 mmHg combination versus 160/97 ± 21/7 mmHg captopril; P < 0.001). Fasting insulin level was raised (7.9 ± 3.6 mU/l combination versus 6.2 ± 3.2 mU/l baseline; P < 0.001). There were no differences between treatments for glucose, urate, cholesterol and triglyceride levels. Serum potassium level was lowered (3.8 ± 0.4 μmol/l combination versus 4.2 ± 0.4 μmol/l captopril, P < 0.05). Postabsorptive endogenous glucose production was raised (10.8 ± 1.7 μmol/kg per min combination versus 10.0 ± 1.5 μmol/kg per min captopril; P < 0.01) and was greater than baseline (9.7 ± 2.1 μmol/kg per min, P < 0.05). Suppression of glucose production by insulin was similar with both treatments. Exogenous glucose infusion rates required to maintain euglycaemia did not differ (32.4 ± 7.6 μmol/kg per min captopril, 32.7 ± 6.2 μmol/kg per min combination, 31.5 ± 7.2 μmol/kg per min baseline). Combination therapy increased glucose production (compared with captopril alone), indicating hepatic insulin resistance. It cannot be assumed that combined preparations with angiotensin converting enzyme inhibitors will ameliorate adverse effects of high doses of thiazide diuretics on insulin action.Keywords
This publication has 36 references indexed in Scilit:
- Insulin action and hepatic glucose cycling in essential hypertensionMetabolism, 1992
- Blood pressure, stroke, and coronary heart diseaseThe Lancet, 1990
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988
- THE COMMUNITY-BASED RANDOMIZED TRIALS OF PHARMACOLOGIC TREATMENT OF MILD-TO-MODERATE HYPERTENSIONAmerican Journal of Epidemiology, 1988
- Insulin Resistance in Essential HypertensionNew England Journal of Medicine, 1987
- Abnormalities of carbohydrate and lipid metabolism in patients with hypertensionArchives of internal medicine (1960), 1987
- MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.BMJ, 1985
- Plasma lipoprotein levels in treated and untreated hypertensive men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1985
- Effect of antihypertensive agents on lipid metabolismThe American Journal of Cardiology, 1983
- CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall StudyThe Lancet, 1980